Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YHA5 | ISIN: US23283M1018 | Ticker-Symbol: 296
Stuttgart
16.07.25 | 07:40
0,256 Euro
-2,29 % -0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CYTODYN INC Chart 1 Jahr
5-Tage-Chart
CYTODYN INC 5-Tage-Chart

Aktuelle News zur CYTODYN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.07.CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab199Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal...
► Artikel lesen
27.06.CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle8
24.06.CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer134VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
16.05.CytoDyn Inc. - 8-K, Current Report8
15.05.CytoDyn Inc.: CytoDyn Releases ESMO Breast Cancer Meeting Poster10
13.05.CytoDyn Inc.: CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors10
CYTODYN Aktie jetzt für 0€ handeln
06.05.CytoDyn Inc. - 8-K, Current Report15
06.05.CytoDyn appoints Robert Hoffman as CFO8
06.05.CytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer383VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
29.04.CytoDyn Inc.: CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany13
14.04.CytoDyn Inc. - 10-Q, Quarterly Report5
18.03.CytoDyn Inc.: March 2025 Letter to Shareholders1.051VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24...
► Artikel lesen
24.02.CytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab355VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
06.02.CytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories283VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
17.12.24CytoDyn Inc.: December 2024 Letter to Shareholders377VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. ("CytoDyn" or the "Company") achieved multiple crucial milestones...
► Artikel lesen
04.11.24CytoDyn Inc.: CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial279VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
04.10.24CytoDyn Inc.: CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial313VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
09.09.24CytoDyn Inc.: September 2024 Letter to Shareholders347VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. ("CytoDyn" or the "Company"). A year in which we have made significant...
► Artikel lesen
03.09.24Biotech-Favorit im September: Ocugen, Novavax, Clinuvel, Cytodyn1.996Immer mehr Profis erwarten eine neue Biotech-Hausse und positionieren sich für eine lange Rallye im Sektor. Cleveres Stockpicking ist jetzt entscheidend. Der anlaufende Monat September, ein historisch...
► Artikel lesen
12.08.24CytoDyn Inc.: CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer236VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2